Neuropathology

AltPep Study Published in Nature Journal, Scientific Reports, Further Affirms Potential of Blood Test to Detect Alzheimer's Disease

Retrieved on: 
Friday, April 5, 2024
Research, Neurology, Publishing, Communications, Clinical Trials, Biotechnology, Managed Care, Health, Science, Plasma, Scientific Reports, Patient, University, Amyloid, Neuropathology, MCI, Pharmaceutical industry

The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.

Key Points: 
  • The data, consistent with an earlier study , further support the potential value of the SOBA-AD test as a promising blood-based tool for the selective detection and confirmation of AD.
  • The SOBA-AD blood test targets toxic soluble oligomers, an early molecular trigger of amyloid diseases, with the ultimate goal of identifying patients with the disease years before symptoms manifest.
  • The SOBA-AD blood test identified AD patients from cognitively unimpaired (CU) subjects with 100% sensitivity, >95% specificity, and >98% area under the curve (95% CI 0.95-1.00).
  • These results for our simple SOBA-AD blood test support the goal of earlier, pre-symptomatic detection of patients with AD.

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Retrieved on: 
Wednesday, February 14, 2024
Inflammasome, PD, NLRC4, ALS, ASC, Inflammation, Traumatic brain injury, Nature Reviews Neurology, Neurology, Extracellular space, Neuropathology, Stroke, TBI, NLRP1, Multiple sclerosis, Intellectual disability, Therapy, Super Meat Boy, DSM-IV codes, Epilepsy, AIM2, Brain, Pharmaceutical industry

The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.

Key Points: 
  • The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.
  • ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes to block initiation and perpetuation of damaging inflammation.
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a review article published in Nature Reviews Neurology.
  • The authors concluded, “Use of inflammasome-targeted therapeutic approaches could improve existing therapeutic strategies for multiple neurological conditions.” To review the publication, Click Here .

Researchers Identify New Cost Savings and Accuracy of C2N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease

Retrieved on: 
Thursday, November 16, 2023
Research, Other Health, General Health, Pharmaceutical, Mental Health, Medical Devices, Clinical Trials, Science, Neurology, Biotechnology, Medical Supplies, Health, Other Science, Classification, Hypertension, Associate, Brain, Diagnosis, Deficit spending, RUO, APS2, CBD, Pathology, Ageing, AUC, Amyloid, Plasma, Disease, Peptide, CLIA, PSP, CSF, Non-fungible token, Patient, Research and development, LDT, MCI, FDA, Neuropathology, FTD, C2N, Physiology, Therapy, Dementia, Frontotemporal dementia, University, Corticobasal degeneration, Development, Clinical trial, Body mass index, Emilie Rissman, Biomarker, PET, Diabetes, Medical imaging, Medical device, Alzheimer's disease, Biostatistics, Medicine, Neuroscience

Dr. Joel Braunstein, CEO of C2N Diagnostics, said, “This year’s CTAD conference was a great success for C2N Diagnostics and the field as a whole.

Key Points: 
  • Dr. Joel Braunstein, CEO of C2N Diagnostics, said, “This year’s CTAD conference was a great success for C2N Diagnostics and the field as a whole.
  • Many independent researchers and collaborators presented important findings about our Precivity line of blood tests, affirming these clinical tools are aiding healthcare providers in the diagnosis and treatment of Alzheimer’s disease.
  • The tests are also helping researchers address key biological questions about the disease, who is at elevated risk, and how blood tests can help in everyday clinical practice.
  • The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.

Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy

Retrieved on: 
Thursday, October 5, 2023
Interneuron, Neuropathology, Temporal lobe epilepsy, RNA, Clinical, Cell, GABAergic, B cell, DSM-IV codes, Survival, MGE, Generalized tonic–clonic seizure, Epilepsy, Transplant, Translation, GMP, Cell Stem Cell, Therapy, GABA, Seizure, Clinical trial, History, SAN, Tissue, Behavior informatics, Patient, Pharmaceutical industry, Vaccine, Sarcocystis neurona

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy. In a preclinical study, administration of a single dose of the cells in a chronic model of drug-resistant MTLE resulted in durable and consistent suppression of focal seizures, as well as improvements in neuropathology and an increase in survival of the model. The study also demonstrated a potentially broad, safe and effective dosing range in the preclinical model. The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE (NCT05135091). The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online.

Key Points: 
  • The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE ( NCT05135091 ).
  • The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online .
  • “We are thrilled to announce this landmark publication, which builds the foundation for NRTX-1001 and exemplifies the phenomenal science being conducted by Neurona employees.
  • The data support the development of Neurona’s cell therapy candidate NRTX-1001, which is being evaluated in an ongoing clinical trial ( NCT05135091 ) in adults with drug-resistant MTLE.

The Inner Circle Acknowledges, Dennis K. Burns as a Pinnacle Life Member for his contributions to the field of Neuropathology

Retrieved on: 
Tuesday, September 12, 2023
Tissue, University of Texas Southwestern Medical Center, State, University, Education, Emeritus, American Board of Pathology, Teaching, Multimedia, History, Alpha Omega Alpha, Science, Inner circle, American Board of Commissioners for Foreign Missions, Tuskegee Veterans Administration Medical Center, Baylor University, MD, Physician, Parkland Memorial Hospital, Diagnosis, Health, Family, Distinguishing, Disease, Nursing, Pathology, Chemistry, Neuropathology

DALLAS, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dennis K. Burns is acknowledged as a Pinnacle Life Member for his contributions to the field of Neuropathology.

Key Points: 
  • DALLAS, Sept. 11, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dennis K. Burns is acknowledged as a Pinnacle Life Member for his contributions to the field of Neuropathology.
  • Dr. Burns launched his pursuit of higher education at Baylor University where he earned a Bachelor of Science degree in Chemistry in 1974.
  • He then attended Texas Southwestern Medical School where he received an MD in 1978.
  • The doctor capped his formal education with fellowships in surgical pathology and neuropathology completed at the University of Texas Southwestern from 1978 to 1985.

Stanford Pathology Chair and Expert in Alzheimer's and Parkinson's Disease Joins Enable Medicine's Scientific Advisory Board to Advance Digital Pathology Capabilities

Retrieved on: 
Wednesday, June 14, 2023
American Association of Neuropathologists, National Science Advisory Board for Biosecurity, Drug development, University, Alzheimer's disease, Stanford University, Marie Cassidy, NIA, United States Air Force Scientific Advisory Board, Intelligence, Research, Stanford University Medical Center, Advisory board, Parkinson's disease, Neuropathology, University of Washington Department of Global Health, NINDS, NIH, Medicine, National Alzheimer's Project Act, Medical device, Pathology

MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Enable Medicine announced today that Dr. Thomas Montine has joined its Scientific Advisory Board .

Key Points: 
  • MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Enable Medicine announced today that Dr. Thomas Montine has joined its Scientific Advisory Board .
  • Dr. Montine joins eight other leaders in the fields of artificial intelligence, drug development, and oncology on the Advisory Board.
  • Dr. Montine is the Chair of the Department of Pathology at Stanford University where he is the Stanford Medicine Endowed Professor in Pathology and is on the Board of Directors of Stanford Health Care.
  • Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States.

Global Custom Antibody Market Report to 2030: Increasing Demand for Customized Diagnostics and Therapeutics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023
Health, Pharmaceutical, Mouse, Central nervous system, Sigma-Aldrich, Neoplasm, Infection, Cancer, Antibody, Research, Monoclonality, USD, ATRX, Incidence, Developed country, Application, Engineering, Growth, Neuropathology, Glioma, Fine chemical, Vaccine, Pharmaceutical industry

The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030.

Key Points: 
  • The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030.
  • Additionally, rising awareness of personalized diagnostic and therapeutic treatments in emerging markets is also a contributing factor to the growth of the custom antibody market.
  • However, the high cost of producing custom monoclonal antibodies is expected to restrain the growth of the custom antibody market.
  • The increasing R&D investment by companies is expected to support the growth of the custom antibody market
    By service, the antibody development segment captured the majority of the custom antibody market share in 2022.

AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting

Retrieved on: 
Thursday, May 18, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Tissue, Central nervous system, Gene, Comorbidity, Gastrointestinal disease, Health care, Food, Aes, Food and Drug Administration, Skin, Liver, Brain, SOC, Stem cell, Beery, Cystinosis, Metabolism, AVRO, Cystine, Clinical trial, Patient, Standard of care, Blood, Cell, Cysteamine, HSC, MRCP, FDA, FFPM, Safety, Neuropathology, Society, DSM-IV codes, MHRA, Disease, Pharmaceutical industry, Vaccine, Medical imaging

These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.

Key Points: 
  • These data are being presented at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles, California, on May 18, 2023.
  • “We are excited about moving this investigational gene therapy closer to patients.”
    In addition to the data presented, the Company also announced positive and productive meetings with the U.K.
  • Preliminary data from this trial suggest that this HSC gene therapy is well tolerated, with no AEs related to the drug product to date.
  • An oral presentation by Dr. Cherqui on these data, “Phase 1/2 Clinical Trial of Autologous Hematopoietic Stem and Progenitor Cell Gene Therapy for Cystinosis,” will occur today at 3:45 PM PT in the session Metabolic, Storage, Endocrine, Liver and Gastrointestinal Disease II of the ASGCT Annual Meeting.

NICO Awards $40,000 Grant to Study Genetic & Biological Make-Up of Meningioma Brain Tumors

Retrieved on: 
Thursday, May 4, 2023
Maintenance, Brain, APS, Classification, Small RNA, Spinal cord, NCI-designated Cancer Center, IIS, Prognosis, Research, Biomarker, RNA, Doctor of Philosophy, Crystal skull, OSU, DSM-IV codes, NICO, MD, Patient, Collection, Pathology, Physician, Paraffin, Biology, Neoplasm, Neuropathology, Microdissection, Health, Recurrence, Malignancy, Tumor microenvironment, Medical imaging, Meningioma

INDIANAPOLIS, May 4, 2023 /PRNewswire/ -- NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, has awarded a $40,000 grant to Daniel Prevedello, MD, vice chair for Academic Affairs and director of Skull Base and Pituitary Surgery Programs at the Ohio State University (OSU) Comprehensive Cancer Center. The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions. Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.

Key Points: 
  • The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions.
  • Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.
  • Study on progression & recurrence of the most common brain tumor, meningioma, could guide new patient care decisions.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

Gene therapy candidate for amyotrophic lateral sclerosis (ALS) demonstrates bioactivities in a murine model of the disease

Retrieved on: 
Monday, March 13, 2023
Friedreich's ataxia, Respiratory failure, CNS, Muscular dystrophy, Animal, Cell, Sporadic group, Spinal cord, Atrophy, SOD1, Excitotoxicity, OTC, LEAS, ALS, Multiple sclerosis, Gene, AAV, Death, Nervous system, Brain cell, Oxidative stress, Rare, RNA, Risk, Muscle atrophy, Multimedia, European Society of Gene and Cell Therapy, Facial muscles, DNA, Myasthenia gravis, Denervation, DSM-IV codes, Diagnosis, Neuropathology, Tetraplegia, Messenger, Nerve, Drug Quality and Security Act, Therapy, The Company, Human, FINRA, Cancer, Motor cortex, Survival, Patient, Vaccine, Dietary supplement

Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.

Key Points: 
  • Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.
  • The technology was licensed on an exclusive worldwide basis from the Universitat Autonomo de Barcelona in Barcelona, Spain.
  • The overexpression of the SOD1 gene in humans is called "familial ALS" and occurs in 5%-10% of all ALS cases.
  • The delivery and expression of the s-KL protein by the s-KL gene may be an effective therapy in this degenerative neuromuscular disease" said Dr. Sinkule.